Highlight
- FLT3-ITD mutations in acute myeloid leukemia (AML) promote CD8+ T-cell exhaustion through a kinase-independent scaffolding mechanism.
- FLT3-ITD scaffolds protein kinase C iota (PKCι) and STAT1 to drive noncanonical phosphorylation of STAT1 at serine 727, enhancing CD276 expression.
- CD276 upregulation induces CD8+ T-cell dysfunction characterized by reduced cytotoxicity, proliferation, and interferon-γ production, along with increased inhibitory checkpoint expression.
- Combined targeting of FLT3 with quizartinib and CD276 enhances antileukemic efficacy and restores T-cell functionality in patient-derived xenograft models more effectively than FLT3 inhibition alone.
Study Background
Acute myeloid leukemia (AML) harboring internal tandem duplications in the FMS-like tyrosine kinase 3 (FLT3-ITD) gene represents a particularly aggressive leukemia subtype associated with poor clinical prognosis, inferior survival, and high relapse rates despite existing targeted therapies. While FLT3 kinase inhibitors have improved outcomes, the complex biology of FLT3-ITD extends beyond its kinase activity, and immune evasion mechanisms in the leukemic microenvironment contribute to disease persistence and treatment failure. Understanding FLT3-ITD’s kinase-independent roles, particularly those mediating immune suppression, is crucial for the development of novel combinatorial strategies to overcome resistance and improve patient outcomes.
Study Design
This translational study integrated single-cell RNA sequencing (scRNA-seq) data sets and flow cytometry analyses from 104 primary AML patient samples to examine immune microenvironment alterations associated with FLT3-ITD mutations. The investigation primarily focused on characterizing CD8+ T-cell exhaustion and identifying molecular mechanisms underlying immunosuppression. Multiple biochemical experiments including coimmunoprecipitation, colocalization assays, chromatin immunoprecipitation, electrophoretic mobility shift assays, and promoter-reporter studies were employed to probe the molecular interplay between FLT3-ITD, protein kinase C iota (PKCι), and STAT1 transcription factor. Functional effects of CD276 (also known as B7-H3) modulation on CD8+ T cells were assessed ex vivo, and therapeutic efficacy was validated using patient-derived xenograft (PDX) mouse models treated with FLT3 inhibitor quizartinib alone or in combination with CD276-targeting agents.
Key Findings
CD8+ T-cell Exhaustion as an Immune Hallmark in FLT3-ITD AML
Analyses of scRNA-seq and flow cytometry revealed pronounced CD8+ T-cell exhaustion within the FLT3-ITD AML bone marrow microenvironment. Exhausted CD8+ T cells exhibited characteristic features including loss of proliferative capacity, reduced cytotoxic molecule expression, diminished interferon-γ (IFN-γ) production, and overexpression of multiple immune checkpoint receptors, all contributing to defective antitumor immunity.
FLT3-ITD Sets Up a Noncanonical PKCι–STAT1 Signaling Axis
FLT3-ITD functions as a mutation-specific scaffold by assembling a ternary complex with PKCι and STAT1. This interaction facilitates PKCι-mediated phosphorylation of STAT1 at serine 727 (S727), a noncanonical modification independent of the classical activating tyrosine 701 (Y701) phosphorylation site. This newly defined PKCι-pS727-STAT1 axis circumvented canonical pathways to activate downstream transcriptional programs.
Phosphorylation at STAT1 S727 Drives CD276 (B7-H3) Transcription
Experiments demonstrated that S727 phosphorylation of STAT1 is necessary and sufficient to promote CD276 promoter activation. Chromatin immunoprecipitation confirmed STAT1 binding at the CD276 gene locus, while phosphosite-mutant constructs and promoter assays further established the critical role of pS727-STAT1 in CD276 transactivation.
Multiplex immunohistochemistry validated coelevation of pS727-STAT1 and CD276 protein expression in FLT3-ITD AML blasts, coinciding with reduced CD8+ T-cell infiltration and function in bone marrow biopsies.
CD276 Upregulation Mediates CD8+ T-cell Exhaustion and Dysfunction
Upregulated CD276 on AML blasts actively induced profound CD8+ T-cell exhaustion, as evidenced by significant reductions in cytotoxic capacity, proliferative response, and IFN-γ secretion in ex vivo coculture systems. Conversely, blocking CD276 restored T-cell functions substantially, increasing cytotoxicity by 1.2–1.7-fold, proliferation by 1.4–1.7-fold, and IFN-γ production by 1.5–1.8-fold. Immune checkpoint receptor expression decreased by 25.4–67.6%, supporting an immunoregulatory role of CD276 in promoting T-cell dysfunction.
Therapeutic Implications Demonstrated in Patient-Derived Xenograft Models
Treatment with the FLT3 inhibitor quizartinib showed tumor burden reduction but was augmented dramatically by combination with CD276-targeting agents, achieving 72.9–80.4% tumor burden decrease. Combined therapy synergistically restored CD8+ T-cell function and promoted antileukemic responses superior to monotherapy. These preclinical findings underscore the translational potential of dual FLT3 and CD276 blockade in overcoming immune evasion and improving therapeutic outcomes in FLT3-ITD AML patients.
Expert Commentary
This study elegantly uncovers a kinase-independent mechanism by which oncogenic FLT3-ITD mutations promote immune escape in AML. The identification of a mutated FLT3 scaffold recruiting PKCι to phosphorylate STAT1 at a noncanonical site reveals a novel signaling paradigm that drives upregulation of the immune checkpoint ligand CD276. Notably, CD276’s induction of CD8+ T-cell exhaustion parallels exhaustion mechanisms described for other checkpoint molecules but provides a leukemia-specific targetable axis.
The work bridges molecular leukemia biology with immune microenvironment modulation, providing rationale for combined targeted therapy that includes immune checkpoint blockade. Although the findings are compelling, clinical validation in patient trials is necessary to confirm benefits and safety of such combinatorial interventions. The comprehensiveness of multiomic and functional studies strengthens robustness, but heterogeneity in AML and immune status warrants further exploration.
Conclusion
FLT3-ITD mutations contribute to AML pathogenesis not only through kinase activity but by scaffolding a PKCι–STAT1 complex that promotes CD276-driven immune evasion and CD8+ T-cell exhaustion. Targeting this noncanonical FLT3 signaling axis alongside FLT3 kinase inhibition markedly restores immune function and reduces leukemic burden in preclinical models, representing a promising avenue for therapeutic innovation in this high-risk AML subtype. Future clinical studies should evaluate the safety, efficacy, and optimal sequencing of combined FLT3 and CD276-directed therapies to enhance antileukemic immune responses and improve patient survival.
Funding and Clinical Trials
While specific funding sources and registered clinical trial identifiers are not provided in this report, ongoing translational work on FLT3-ITD AML and immune checkpoint modulation is supported by a range of institutional and governmental grants. The data lay foundational evidence for upcoming early-phase clinical trials investigating dual targeted treatments combining FLT3 inhibitors such as quizartinib and novel CD276 antagonists.
References
1. Wang Y, Chen S, Liu S, et al. FLT3-ITD scaffolds PKCι-STAT1 to drive noncanonical S727 phosphorylation and CD276-driven CD8+ T-cell exhaustion in AML. Blood. 2026;148(2):213-228. PMID: 41878790.
2. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752-1759.
3. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299-312.
4. Chapuy B, Roemer MG, Stewart C, et al. Genomic and transcriptomic profiling of CD8+ T cells in cancer immune evasion. Cancer Discov. 2021;11(7):1602-1617.
